Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL8308271 | 0.92 | ALDH1A1 (0.56) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL6889633 | 0.88 | KDM4E (0.64) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL5925291 | 0.84 | TDP1 (0.65) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL2747973 | 0.83 | TDP1 (0.70) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL51601 | 0.81 | TDP1 (0.68) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL137486 | 0.81 | TDP1 (0.83) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL28875175 | 0.81 | TDP1 (0.68) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL1774775 | 0.80 | TDP1 (0.73) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL2649692 | 0.79 | TDP1 (0.78) | TDP1MAPK1HIF1ASLC6A2SLC6A3 | |
| SCHEMBL13292516 | 0.79 | TDP1 (0.79) | TDP1MAPK1HIF1ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1275989-C | Water-soluble poly-p-phenylene ethynylene and synthetic method | UNIV FUDAN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1600796-A | Water-soluble poly-p-phenylene ethynylene and synthetic method | UNIV FUDAN (CN) | 2005-03-30 | — | — | CN | claimed |
| EP-4658663-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20240287124-A1 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024163262-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-112714649-B | Cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| WO-1996034868-A1 | ESTERS OF CARBAPENEMS | SMITHKLINE BEECHAM PLC (GB) | 1996-11-07 | — | — | WO | disclosed |
| WO-1996026929-A1 | 4-AMINOTETRAHYDROBENZISOXAZOLE OR -ISOTHIAZOLE COMPOUNDS | H. LUNDBECK A/S (DK) | 1996-09-06 | — | — | WO | disclosed |
| US-5389626-A | 3-aryloxmethyl-cephalosporin derivatives, and their medical use | SANKYO COMPANY, LIMITED (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0479951-A4 | BIS-ACYLOXYMETHYL DERIVATIVES | — | 1992-12-09 | — | — | EP | disclosed |
| EP-0479951-A1 | BIS-ACYLOXYMETHYL DERIVATIVES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1992-04-15 | — | — | EP | disclosed |
| WO-1991000093-A1 | BIS-ACYLOXYMETHYL DERIVATIVES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1991-01-10 | — | — | WO | disclosed |
| CN-1042153-A | 3-aryloxy methyl-cephalosporins derivatives, their preparation and purposes pharmaceutically | SANKYO CO (JP) | 1990-05-16 | — | — | CN | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-4159372-A | Process for preparing cephalosporin esters in the presence of liquid sulfur dioxide | MEIJI SEIKA KAISHA LTD. (JP) | 1979-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287124-A1 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DNTT, NAPRT, NAMPT | TDP1 254/4885MAPK1 3748/4885HIF1A 2718/4885 |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | TDP1 722/4885MAPK1 3057/4885HIF1A 3257/4885 |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | TDP1 733/4885MAPK1 3100/4885HIF1A 3347/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | TDP1 733/4885MAPK1 3100/4885HIF1A 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.